Gyeongbuk Kick-Starts Vaccine Industry with ‘Global Vaccine Industry Forum 2016’
- More than 200 experts from industry, academia, research institutes from Korea and abroad, including IVI, in attendance
- MOU between IVI, Gyeongbuk (province), Andong (city) signed; keynote speech, presentations, discussions delivered
- Officials from global vaccine enterprises including GSK, Sanofi Pasteur, Bill & Melinda Gates Foundation invited to attend
Gyeongsangbuk-do (Gyeongbuk or North Gyeongsang Province) held the opening ceremony of the ‘Gyeongbuk Global Vaccine Industry Forum 2016’ at Richell Hotel in Andong on September 9 to seek to set direction and strategy for development of the vaccine industry, form a network with domestic and overseas partners, and expedite mutual exchange in order to lay the foundation to nurture the vaccine industry.
Held under the theme “Present and Future of Globalization of the Korean Vaccine Industry,’ the forum is taking place on September 8 - 10. The opening ceremony on September 9 was a huge success, as it brought together more than 200 vaccine experts and officials including Gyeongbuk Governor Kim Kwan-yong, Rep. Kim Kim Gwang-lim, Andong Mayor Kwon Young-se, and Jerome Kim, Director General of the International Vaccine Institute.
The event attracted keen attention since it was organized as an international forum with companies from the Korean vaccine industry as the primary focus. The forum is significant in that it brought together key players in the global vaccine industry, including global companies such as GSK Biologics of Belgium, No. 1 player in market share in the world, Janssen of the U.S., and Sanofi Pasteur of France, as well as IVI, an international organization devoted to vaccines for developing countries, and the Bill & Melinda Gates Foundation.
Prior to the opening of the forum, Gyeongbuk signed an MOU with IVI and Andong-si to promote the Vaccine Industry Cluster and vaccine development, and agreed to cooperate in vaccine R&D and industrialization, dissemination and introduction of vaccines in developing countries, mutual exchange to expedite exchange of technology and information with the aim of developing the vaccine industry. With the signing of the MOU, which follows an agreement to establish an IVI branch laboratory (April 2015) (in the cluster), Gyeongbuk is expected to play a major role in the development of the vaccine industry as a partner for research, development and industrialization aimed at establishment and galvanizing of the Vaccine Industry Cluster in collaboration with IVI.
Representatives from the parties pose for a photo after signing an MOU beweeen the Gyeongsangbuk-do province, Andong City, and IVI to promote vaccine development and the new vaccine industry cluster in the province, ahead of the opening of the 2016 Gyeongbuk Global Vaccine Industry Forum on September 9. From left: Andong Mayor Kwon Young-se, IVI Director General Dr. Jerome Kim, and Jung Byung-woon, Vice Governor of Gyeongsangbuk-do.
The forum, which takes place amid growing interest in infectious diseases such as MERS and the Zika virus that caused outbreaks in Korea and overseas, shed lights on future vision for globalization of the Korean vaccine industry, and to present measures for global cooperation to deal with infectious diseases.
In his keynote speech, Dr. Jerome Kim, an world leading authority in the vaccine field and Director General of IVI, a global public-sector organization for vaccine development, addressed ‘Vaccines for Global Health,’ and debriefed on the background for establishment of IVI mandated for discovery, development, and delivery of vaccines for global public health, introduced successful cases of vaccine development in partnership with Korean vaccine companies, and projected a vision for IVI’s future.
Dr. Jerome Kim said, “IVI is excited to partner with Gyeongbuk and Andong to promote vaccine development, and have the opportunity to assist the globalization and growth of the Korean vaccine industry,” adding, “This partnership will add momentum to our concerted efforts to bring new vaccines to the global market from this emerging Vaccine Industry Cluster and Korean vaccine manufacturers and to advance global public health.”
In the subsequent morning session, Johan Van Hoof, head of the infectious diseases & vaccine business at Janssen, gave a talk entitled ‘Vaccine Industry and Global Community’ while Hani Kim, program officer at the Gates Foundation,’ emphasized global vaccine industry partnership through her talk ‘A World of Good: Partnering to Support Global Health.’
The afternoon sessions entailed lectures by experts from Korea and overseas to address the themes ‘Trends in Global Vaccine Industry’ and ‘the Present and the future of the global industrialization of the domestic vaccine industry.’ A panel discussion session under the theme ‘Present and future of global vaccine industrialization in Korea,’ reviewed competitiveness of the Korean vaccine industry that has made achievements recently in the global market, and discussed strategy and key measures to expedite its growth into a global industry, while presenting vision for the future and envisioning the development of the global vaccine industry.
Gyeongbuk has been making far-reaching preparations to establish the Vaccine Industry Cluster and to construct related infrastructure to globalize the vaccine industry. Starting with the bio industry complex aimed at clustering the vaccine industry, the province is seeking to designate a Bio Vaccine Cluster, and expand Second Gyeongbuk Bio Industry Complex. It constructed SK Chemicals vaccine plant, the first cell culture-based vaccine manufacturing plant in Korea, which started commercial operation last year, while ground was broken to construct SK plasma blood product plant. Also, 21 vaccine-related companies expressed interest to join in the effort to develop the Vaccine Industry Cluster, and as a result the cluster is expected to attract a number of vaccine-related firms. Notably, a branch lab of IVI, an international organization, will be launched in the cluster in November this year.
In addition, Andong National University will open a ‘vaccine engineering department’ that will nurture professional manpower for vaccine industry for the first time in Korea, while ‘Gyeongbuk executive ordinance for development and support of the vaccine industry’ was enacted last year, which provides institutional framework to nurture and develop the vaccine industry into Gyeongbuk’s innovation-driven new growth engine for the future.
Recently, the province passed a preliminary feasibility review of a project to construct industrial foundation for globalization of the vaccine industry, which is pushed for by the central government. As a result, the province is seeking to construct an ‘animal cell validation assistance center’ with 102.9 billion won for five years beginning in 2017, laying the foundation to strengthen global competitiveness for vaccine production.
Gyeongbuk Governor Kim Kwan-yong said, “We will develop the vaccine industry, and create high-tech medical cluster encompassing vaccine in Andong, Asian medicine in Gyeongsan, and accelerator-based new drugs in Pohang, and thereby develop Gyeongbuk into a hub of the new Korean medical industry. By constructing a global vaccine industry cluster and industrialization, Gyeongbuk will take the lead in Korea’s effort to secure vaccine sovereignty (security), and emerge as one of the top 5 vaccine producers in the world through industrialization of the vaccine industry.
The International Vaccine Institute (IVI) is the world’s only international organization devoted exclusively to developing and introducing new and improved vaccines to protect the world’s poorest people, especially children in developing countries. Established in 1997, IVI operates as an independent international organization under a treaty signed by 35 countries and the World Health Organization. The Institute conducts research in more than 20 countries of Asia, Africa and Latin America on vaccines against enteric and diarrheal infections, Japanese encephalitis, MERS, and dengue fever, and develops new and improved vaccines at its headquarters in Seoul, Republic of Korea. For more information, please visit http://www.ivi.int .
Tae Kyung Byun
Senior Manager, Korean Communications
Phone: +82-2-872-2801 (Ext. 159)